Literature DB >> 2677743

Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator.

L Rimsky1, M D Dodon, E P Dixon, W C Greene.   

Abstract

The rex gene of the type I human T-cell leukaemia virus (HTLV-I) encodes a phosphorylated nuclear protein of relative molecular mass 27,000 which is required for viral replication. The Rex protein acts by promoting the cytoplasmic expression of the incompletely spliced viral messenger RNAs that encode the virion structural proteins. To identify the biologically important peptide domains within Rex, we introduced a series of mutations throughout its sequence. Two distinct classes of mutations lacking Rex biological activity were identified. One class corresponds to trans-dominant repressors as they inhibit the function of the wild-type Rex protein. The second class of mutants, in contrast, are recessive negative, rather than dominant negative, as they are not appropriately targeted to the cell nucleus. These results indicate the presence of at least two functionally distinct domains within the Rex protein, one involved in protein localization and a second involved in effector function. The trans-dominant Rex mutants may represent a promising new class of anti-viral agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677743     DOI: 10.1038/341453a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  Anti-Rex aptamers as mimics of the Rex-binding element.

Authors:  S Baskerville; M Zapp; A D Ellington
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

Authors:  D McDonald; T J Hope; T G Parslow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.

Authors:  L Solomin; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Mutational analysis of the human T-cell leukemia virus type I trans-acting rex gene product.

Authors:  L Hofer; I Weichselbraun; S Quick; G K Farrington; E Böhnlein; J Hauber
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for trans dominance.

Authors:  I Weichselbraun; J Berger; M Dobrovnik; H Bogerd; R Grassmann; W C Greene; J Hauber; E Böhnlein
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

7.  Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex are functionally interchangeable and share an essential peptide motif.

Authors:  T J Hope; B L Bond; D McDonald; N P Klein; T G Parslow
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Definition of the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex protein activation domain by functional exchange.

Authors:  I Weichselbraun; G K Farrington; J R Rusche; E Böhnlein; J Hauber
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Posttranscriptional effector domains in the Rev proteins of feline immunodeficiency virus and equine infectious anemia virus.

Authors:  V A Mancuso; T J Hope; L Zhu; D Derse; T Phillips; T G Parslow
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.